SkinBioTherapeutics (LON:SBTX) Shares Down 5.7% – Time to Sell?

SkinBioTherapeutics plc (LON:SBTX)’s share price was down 5.7% during mid-day trading on Friday . The company traded as low as GBX 5 and last traded at GBX 5.66. Approximately 6,453,143 shares traded hands during trading, an increase of 9% from the average daily volume of 5,934,484 shares. The stock had previously closed at GBX 6.

SkinBioTherapeutics Trading Up 8.9%

The firm has a market cap of £16.21 million, a price-to-earnings ratio of -20.19 and a beta of 2.01. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The company’s 50 day simple moving average is GBX 16.54 and its 200 day simple moving average is GBX 15.77.

SkinBioTherapeutics (LON:SBTX) last released its earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.